Table 3.
Electrochemical Method | Target Biomarker | Linear Range | LOD | Biological Sample | Ref. |
---|---|---|---|---|---|
DPV measurement | S1 spike protein | 5.0–500 ng/mL | 2.9 ng/mL | Human serum | [42] |
Paper based electrochemical measurement | RNA of the N gene | 585.4–5.854 × 107 copies/μL | 6.9 copies/μL | Nasopharyngeal swab | [43] |
DPV measurement | Spike protein | 0.04–10 μg/mL | 19 ng/mL | Untreated saliva | [44] |
Nucleocapsid protein | 0.01–0.6 μg/mL | 8.0 ng/mL | |||
DPV measurement | ORF1ab | 10−2 fM-1.0 pM | 200 copies/mL | Throat swab, Urine, Feces, Plasma, Whole blood, Saliva | [45] |
DPV measurement | Nucleocapsid protein | 0.22–333 fM | 27 fM | Nasopharyngeal swab | [46] |
EIS measurement | S protein | 1.0 fM-1.0 nM | 2.8 fM | Fetal bovine Serum, Rabbit Serum | [47] |
RBD | 16.9 fM | ||||
SWV measurement | SP-RBD | 1.0–1000 ng/mL | 0.11 ng/mL | Human sera | [48] |
SWV measurement | SARS-CoV-2 spike antibody | 0.1–1000 ag/mL | 0.01 ag/mL | Pretreated saliva and oropharyngeal swab | [49] |
DPV measurement | MNP-S1/anti-S1 Ab | 2.5–200 ng/mL | 0.93 ng/mL | Nasopharyngeal swab (original, alpha, beta, and delta variants) | This work |
MNP-S1/Ab cocktail | 1.0–200 ng/mL | 0.53 ng/mL | |||
MNP-S2/anti-S2 Ab | 1.0–200 ng/mL | 0.99 ng/mL | |||
MNP-S2/Ab cocktail | 2.5–100 ng/mL | 0.75 ng/mL |
AuNP: Gold nanoparticle, Cys: Cysteamine, DPV: Differential pulse voltammetry, EIS: Electrochemical impedance spectroscopy, FET: Field-effect transistor, LSG: Laser-scribed graphene, MNP: Magnetic nanoparticles, ORF: Open reading frame, PBASE: 1-pyrenebutyric acid N-hydroxysuccinimide ester, RBD: Receptor binding domain, SP-RBD: Spike protein receptor-binding domain, SWV: Square-wave voltammetry.